Loading market dashboard
Silexion Therapeutics Ltd.
SLXNHealthcareNASDAQIL
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
Trading on split-adjusted basis will begin at market open on May 29, 2026. This adjustment is expected to help Silexion comply with Nasdaq requirements, enhance its market position, and support its progress in developing SIL204. Trading on split-adjusted basis will begin at market open on May 29, 2026. This adjustment is expected to help Silexion comply with Nasdaq requirements, enhance its market position, and support its progress in developing SIL204.
Israeli Ministry of Health approved the initiation of Silexion's Phase 2/3 clinical trial of SIL204 in locally advanced pancreatic cancer
Grand Cayman, May 15, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 1,995,092 of the Company's ordinary shares originally issued in August 2025 and September 2025 having a reduced exercise price of $0.50 per share. The ordinary shares issuable upon exercise of the warrants are registered pursuant to an effective registration statement on Form S-3 (File No. 333-290074) and an effective resale registration statement on Form S-3 (No. 333-291210). The gross proceeds to the Company from the exercise of the warrants are expected to be approximately $1 million, prior to deducting placement agent fees and estimated offering expenses. The offering is expected to close on or about May 18, 2026, subject to satisfaction of customary closing conditions. The Company intends to use the net proceeds from the offering as working capital for general corporate purposes.
Preliminary results from a preclinical study demonstrated statistically significant increase in MHC-I expression following SIL204 treatment in human pancreatic and non-small cell lung cancer cells harboring a KRAS mutation, supporting potential future evaluation alongside anti-PD-1 therapies including pembrolizumab (Keytruda®) Preliminary results from a preclinical study demonstrated statistically significant increase in MHC-I expression following SIL204 treatment in human pancreatic and non-small cell lung cancer cells harboring a KRAS mutation, supporting potential future evaluation alongside anti-PD-1 therapies including pembrolizumab (Keytruda®)
Silexion advances toward Phase 2/3 trial in KRAS-driven pancreatic cancer, as SIL204 begins GMP clinical manufacturing in collaboration with global leading manufacturing partner Catalent at its European center of excellence Tel Aviv Sourasky Medical Center's Helsinki Ethics Committee approves planned Phase 2/3 trial of SIL204 in locally advanced pancreatic cancer, marking an important clinical site activation milestone at a leading Israeli oncology center; Underscores continued regulatory momentum in preparation for trial initiation Grand Cayman, Cayman Islands, May 13, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp.
Silexion advances toward Phase 2/3 trial in KRAS-driven pancreatic cancer, as SIL204 begins GMP clinical manufacturing in collaboration with global leading manufacturing partner Catalent at its European center of excellence
CTA submission positions Silexion for European Phase 2/3 trial of SIL204 in KRAS-driven pancreatic cancer, with Germany serving as Reference Member State for the EU program CTA submission positions Silexion for European Phase 2/3 trial of SIL204 in KRAS-driven pancreatic cancer, with Germany serving as Reference Member State for the EU program
Silexion Therapeutics Corp (NASDAQ: SLXN - Get Free Report) was down 0.9% during mid-day trading on Thursday. The stock traded as low as $1.09 and last traded at $1.11. Approximately 101,379 shares traded hands during mid-day trading, an increase of 36% from the average daily volume of 74,338 shares. The stock had previously closed at
Significant regulatory milestone marks advancement into clinical-stage development of next-generation RNAi therapy featuring an innovative, integrated systemic treatment delivery approach targeting highly prevalent KRAS-driven cancers with significant unmet medical need
Significant regulatory milestone marks advancement into clinical-stage development of next-generation RNAi therapy featuring an innovative, integrated systemic treatment delivery approach targeting highly prevalent KRAS-driven cancers with significant unmet medical need
Throughout the year, the Company reported significant positive preclinical findings for SIL204 across eight KRAS mutations and four cancer types, including first evidence of activity in gastric cancer, reinforcing broad therapeutic potential
